LGC acquires Berry & Associates

News (ZH) - LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of Berry and Associates, premier supplier of specialty oligo reagents.

LGC acquires LINK and strengthens its oligo reagents offering

News (ZH) - LINK Technologies is a premier supplier of speciality reagents for oligonucleotide synthesis

LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids

News (ZH) - Moves strengthen existing analytical and bioanalytical drug development service offering

LGC acquires Prime Synthesis, Inc., and strengthens its supply of oligo synthesis materials

News (ZH) - PSI products complement existing genomics offering

LGC acquires Biosearch Technologies and extends its expertise in the qPCR market

News (ZH) - Acquisition enables enlarged Genomics division to deliver unique product and laboratory services offering for core qPCR and end point PCR applications

Co-Diagnostics, Inc. and LGC Sign License Agreement for CoPrimer Technology

News (ZH) - Exclusive license agreement relates to use of CoPrimer™ technology for both research and commercial applications.

Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK

News (ZH) - Funding to develop liver targeted gene activation therapies

LGC invests in new GMP analytical capability

News (ZH) - The new labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances

OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

News (ZH) - LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme